Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
TScan Therapeutics Pretax Margin % Related Terms
TScan Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRX vs MCRB, HYPD, ELOX: Pretax Margin % Comparison
For the Biotechnology subindustry, TScan Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics (TCRX) has a Pretax Margin % of -2,888.58% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TScan Therapeutics and its competitors. According to the industry distribution chart, TScan Therapeutics ranks #791 out of 945 companies in the Biotechnology industry, placing it in the top 83.7%.
Is TScan Therapeutics' Pretax Margin % too high?
TScan Therapeutics' current Pretax Margin % is -2,888.58%. Based on the distribution chart, TScan Therapeutics ranks #791 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Pretax Margin % compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #791 out of 945 companies for Pretax Margin %. This places TScan Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TScan Therapeutics and its competitors. TScan Therapeutics's current Pretax Margin % is -2,888.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Pretax Margin % is -2,888.58%. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Pretax Margin % is -2,888.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Pretax Margin %: -2,888.58%
GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
